Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- ‘Big data’ definition
- ‘Big data’ criteria – beyond ‘3 vs’
- ‘Big data’ in different fields
- ‘Big data’ criteria in medicinal chemistry
- Entering the ’big data’ era in chemistry
- ChEMBL and PubChem
- Screening hits
- Complex database structure
- Data with varying confidence levels (1)
- Data with varying confidence levels (2)
- Activity measurement-dependent data
- Utility of ‘big data’ in medicinal chemistry
- Promiscuity and polypharmacology
- Assessment of promiscuity degrees
- Recent compound growth
- Compound growth vs. promiscuity
- Rationale for observed promiscuity levels
- Single- vs. multi-target drugs
- Influence of most promiscuous drugs
- Heterogeneity of drug data
- Complexity of drug data
- Data complexity – structural similarity
- Structure-promiscuity relationships
- MMPs formed by bioactive compounds
- MMPs of assay hits
- Drug MMPs
- Drug analogs with different promiscuity
- Data complexity
- Data complexity – assay frequency
- Extensively assayed screening hits
- Assay frequency vs. promiscuity
- Comparable assay frequency; different promiscuity
- Different assay frequency; comparable promiscuity
- Frequency delta does not scale promiscuity delta
- Progression of promiscuity degrees
- Data confidence - promiscuity over time
- Data confidence - Imatinib as an example
- Promiscuity over time: bioactive compounds
- Promiscuity across major target families
- Promiscuity of kinase inhibitors
- Promiscuity of kinase inhibitors - PubChem
- Many kinase inhibitors are quite selective
- Conclusions
Topics Covered
- Big data criteria in medicinal chemistry
- Data at varying confidence levels
- Promiscuity and polypharmacology
- Compound promiscuity analysis in light of big data criteria
- Promiscuity of screening hits
- Promiscuity across major target families
- Promiscuity of kinase inhibitors
Links
Series:
Categories:
Talk Citation
Bajorath, J. and Hu, Y. (2018, January 31). Emerging big data in medicinal chemistry: promiscuity analysis as an example [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/RIUM4822.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Dr. Jürgen Bajorath has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Dr. Ye Hu has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Ye Hu
at the University of Bonn,
and today, I'm going to talk about Emerging Big Data in Medicinal Chemistry.
In particular, promiscuity analysis is chosen as an exemplary topic
or an interesting application for compound data mining.
And this presentation is co-authored with me and my professor, Dr. Jurgen Bajorach.
0:26
As we have noticed,
the big data phenomena has affected essentially all areas of life.
What exactly is big data and how do we define big data?
In 2001, an analyst, Laney
from an information technology firm, Gartner introduced a definition
which states big data is high-volume,
high-velocity and/or high-variety information assets that demand cost-effective,
innovative forms of information processing that enable enhanced insight,
decision making and process automation.
On the basis of this definition, volume,
velocity, and variety would represent characteristic features
or criteria of big data which are often cited as '3 Vs'.
1:21
After over a decade,
the '3 Vs' criteria were extended to '5 Vs'.
Veracity and value were added, indicating that one needs to ensure that
the data are correct and/or the analysis performed on the data is also correct.
All these available data would create a lot of value.
More recently, the '7 Vs' criteria were introduced.
Two more 'Vs', visualization and variability were included.
Visualization is actually the hard part of big data.
Making a large amount of data invisible
and intuitive in a comprehensive manner is not easy at all.
And the big data are often extremely variable.
There is, of course, no reason to limit big data criteria to only those 'Vs'.
However, they will represent the whole of big data issues.
Hide